

## SUPPLEMENTARY METHODS

**Microarray analyses for targets of TNFR2.** Genome-wide extrahepatic bile duct expression datasets have been previously generated and reported by us (deposited in GEO: GSE46995) (8). Statistical significance was determined by unpaired t-test with a significance of  $<0.05$ . To identify molecules linked to TNFR2 function, the ToppGenet algorithm within the Toppgene Suite (<http://toppgene.cchmc.org/>) was utilized to generate a network of TNFR2-interacting proteins, which identified 29 individual molecules. GeneSpring GX13.0 platform was then used to select genes whose expression differed by  $\geq 1.5$ -fold between saline and RRV groups with a significance of  $<0.05$  by Welch one-way analysis of variance (ANOVA) and Benjamini-Hochberg multiple testing correction (false discovery rate [FDR] 0.05).

### Supplementary Table 1

Oligonucleotide primer sequences and PCR product sizes for mouse TNF $\alpha$ -related genes

| Gene         | Mouse Primer Sequences   | Annealing Temp. (°C) | Product Size (bp) |
|--------------|--|----------------------|-------------------|
| <i>Tnfa</i>  | For: 5'-AAGGGAGAGTGGTCAGTTGCC-3'<br>Rev: 5'-CCTCAGGGAAGAGTCTGGAAAGG-3' | 54                   | 95                |
| <i>Tnfr1</i> | For: 5'-ATCCATCAGGGGTCACTGGA-3'<br>Rev: 5'-ACTTGGTGCAGCAGATGGAA-3'     | 60                   | 117               |
| <i>Tnfr2</i> | For: 5'-ACAAACCGGAACCTGGGTAC-3'<br>Rev: 5'-GTCCGAGGTCTTGTTGCAGA-3'     | 60                   | 125               |
| <i>Bmx</i>   | For: 5'-GGAAAGTTCCTGTGTTGCCA-3'<br>Rev: 5'-TGGGAGCTCTGTGTTTCTCA-3'     | 60                   | 117               |
| <i>Ask1</i>  | For: 5'-CAAATCAGACAGTCCGACGG-3'<br>Rev: 5'-GTGCATTCTGGGAGTCATGG-3'     | 60                   | 117               |

## Supplementary Table 2

Statistical analysis of growth profiles, symptoms of cholestasis and Kaplan-Meier survival charts.

A) Statistical analysis of growth curves (weights) of experimental groups (*two-tailed unpaired t test with Welch's correction*):

|              | WT/IgG RRV        | TNFa-Ab RRV  | TNFR1-Ab RRV      | TNFR2-Ab RRV      | TNFR1-KO      | TNFR2-KO          |
|--------------|-------------------|--------------|-------------------|-------------------|---------------|-------------------|
| WT/IgG RRV   | XXX               | <b>0.002</b> | <b>&lt;0.0001</b> | <b>&lt;0.0001</b> | <b>0.11</b>   | <b>&lt;0.0001</b> |
| TNFa-Ab RRV  | <b>0.002</b>      | XXX          | XXX               | XXX               | XXX           | XXX               |
| TNFR1-Ab RRV | <b>&lt;0.0001</b> | XXX          | XXX               | <b>0.48</b>       | XXX           | XXX               |
| TNFR2-Ab RRV | <b>&lt;0.0001</b> | XXX          | <b>0.48</b>       | XXX               | XXX           | XXX               |
| TNFR1-KO     | <b>0.11</b>       | XXX          | XXX               | XXX               | XXX           | <b>0.0011</b>     |
| TNFR2-KO     | <b>&lt;0.0001</b> | XXX          | XXX               | XXX               | <b>0.0011</b> | XXX               |


B) Kaplan-Meier survival plots of experimental groups (*Log-rank [Mantel-Cox] test*):

|              | WT/IgG RRV        | TNFa-Ab RRV   | TNFR1-Ab RRV      | TNFR2-Ab RRV      | TNFR1-KO    | TNFR2-KO     |
|--------------|-------------------|---------------|-------------------|-------------------|-------------|--------------|
| WT/IgG RRV   | XXX               | <b>0.0003</b> | <b>&lt;0.0001</b> | <b>&lt;0.0001</b> | <b>0.94</b> | <b>0.001</b> |
| TNFa-Ab RRV  | <b>0.0003</b>     | XXX           | XXX               | XXX               | XXX         | XXX          |
| TNFR1-Ab RRV | <b>&lt;0.0001</b> | XXX           | XXX               | <b>0.04</b>       | XXX         | XXX          |
| TNFR2-Ab RRV | <b>&lt;0.0001</b> | XXX           | <b>0.04</b>       | XXX               | XXX         | XXX          |
| TNFR1-KO     | <b>0.94</b>       | XXX           | XXX               | XXX               | XXX         | <b>0.01</b>  |
| TNFR2-KO     | <b>0.001</b>      | XXX           | XXX               | XXX               | <b>0.01</b> | XXX          |

C) Comparative analysis of percent mice jaundiced from experimental cohorts of mice (*Wilcoxon matched-pairs signed rank test*):


|              | WT/IgG RRV        | TNFa-Ab RRV       | TNFR1-Ab RRV  | TNFR2-Ab RRV  | TNFR1-KO     | TNFR2-KO     |
|--------------|-------------------|-------------------|---------------|---------------|--------------|--------------|
| WT/IgG RRV   | XXX               | <b>&lt;0.0001</b> | <b>0.0005</b> | <b>0.0012</b> | <b>0.50</b>  | <b>0.001</b> |
| TNFa-Ab RRV  | <b>&lt;0.0001</b> | XXX               | XXX           | XXX           | XXX          | XXX          |
| TNFR1-Ab RRV | <b>0.0005</b>     | XXX               | XXX           | <b>0.21</b>   | XXX          | XXX          |
| TNFR2-Ab RRV | <b>0.0012</b>     | XXX               | <b>0.21</b>   | XXX           | XXX          | XXX          |
| TNFR1-KO     | <b>0.50</b>       | XXX               | XXX           | XXX           | XXX          | <b>0.004</b> |
| TNFR2-KO     | <b>0.001</b>      | XXX               | XXX           | XXX           | <b>0.004</b> | XXX          |

# Supplementary Figure 1




**Supplementary Figure 1. Antibody blocking of TNFR1 and/or TNFR2 does not interfere with NK-cell activation status.** Quantification of activation markers (Mean  $\pm$  SD) on NK cells from in vitro cytotoxicity co-culture assays of mCL and NK cells from RRV-primed mice shows similar levels of Nkg2d and CD69 in the presence of antibodies when compared to isotype control. N=4-6 wells/ratio/specimen. Results are representative of 2 independent experiments with NK cells obtained from a pool of 3-4 livers/specimen. NS=no significant difference as determined by 2-tailed unpaired *t* test.

# Supplementary Figure 2




**Supplementary Figure 2. Antibodies to TNF $\alpha$  decrease portal inflammation in mice with experimental atresia.** Representative hematoxylin/eosin-staining of livers from saline and RRV-injected neonatal mice treated with anti-TNF $\alpha$  or isotype antibodies show decreased portal inflammation in the anti-TNF $\alpha$  group. N=4-6 mice/treatment group/day. Magnification of 400X; scale bar: 50  $\mu$ m.

# Supplementary Figure 3




**Supplementary Figure 3. Genetic deficiency of TNFR2 but not TNFR1 improves hepatic inflammation.** Representative hematoxylin/eosin-staining of livers from *Tnfr1*<sup>-/-</sup> and *Tnfr2*<sup>-/-</sup> mice injected with saline show normal hepatic architecture while livers from RRV-challenged *Tnfr2*<sup>-/-</sup> mice show decreased portal inflammation when compared to *Tnfr1*<sup>-/-</sup> mice. Thin arrows denote intrahepatic bile ducts, arrowheads depict inflammatory cells and block arrows denote areas of parenchymal necrosis and loss of hepatocytes, PV = portal vein. N=4-6 mice/treatment group/day. Magnification: 400X.

# Supplementary Figure 4



**Supplementary Figure 4. TNF $\alpha$ /TNFR signals regulate intrahepatic immune cell populations.** In Panel A, blocking of TNF $\alpha$  suppresses the expansion of hepatic effector T cells (CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup> cells co-stained with CD62L<sup>neg</sup>CD44<sup>hi</sup>), dendritic cells (DC; CD3<sup>neg</sup>CD11c<sup>+</sup>) and NK cells (CD3<sup>neg</sup>CD49b<sup>+</sup>Nkp46<sup>+</sup>). In panel B, the expansion of these cells is suppressed more consistently by antibodies to TNFR2. The same pattern is seen in panel C, where the hepatic population of T, DC and NK cells is suppressed consistently in *Tnfr2*<sup>-/-</sup> mice. Saline and RRV-injected WT mice are depicted for comparison. N=3-4 mice/group. Values are expressed as Mean  $\pm$  SD. \*= $P$ <0.05, \*\*= $P$ <0.01 and \*\*\*= $P$ <0.001 as determined by 2-tailed parametric unpaired *t* test using Welch's correction.



# Supplementary Figure 5



**Supplementary Figure 5. Expression of TNFR-specific molecules in *Tnfr1*<sup>-/-</sup> and *Tnfr2*<sup>-/-</sup> and antibody blocked mice.** Real-time PCR based hepatic mRNA expressions at day 7 after RRV challenge of TNFR1-specific *Ask1* and TNFR2-specific *Bmx* tyrosine kinases in *Tnfr1*<sup>-/-</sup> and *Tnfr2*<sup>-/-</sup> mice (**A**) and antibody blocked (**B**) mice show biological specificities. WT saline and RRV-challenged groups are depicted for comparative purposes. N=4-6 mice/group. Values are expressed as Mean  $\pm$  SD. \$\$\$=P<0.001 (WT saline and RRV) and \*\*\*=P<0.001 (*Tnfr1*<sup>-/-</sup>, *Tnfr2*<sup>-/-</sup>, TNFR1 Ab or TNFR2 Ab treated) as determined by 2-tailed parametric unpaired *t* test using Welch's correction.



# Supplementary Figure 6

**A****B**

**Supplementary Figure 6. Bioinformatics analysis of TNFR2-genes in extrahepatic bile ducts links to STAT1-IRF1 pathway.** (A) Prioritization of TNFR2-neighboring genes by ToppGenet protein-protein interaction network (<http://toppgene.cchmc.org>) identified 29 genes. (B) 15 of these genes were differentially upregulated at day 3, 7 or 14 in extrahepatic bile ducts with greater increases in Stat1 and Irf1 mRNA.